In 2017, F.I.T plans to have net revenue of 2,513 bio dong, profit after tax excluding benefit of non-controlling shareholders of 112 bio dong.
The charter capital is over 2,547 bio dong, consolidated total equity at end of June 2017 is 3,988 bio dong From 2014, F.I.T transformed itself into a holding company, with Mother Company active in investment and subsidiaries focused in some basic industries such as pharma, food, beverage, agriculture, home care and personal care.
From 2017, F.I.T, through Duoc Cuu Long (DCL), has various initiatives in its pharma business including acquiring Euvipharm from Valeant – Canada and starting a new capsule factory. Beside, a new joint venture in oncology was established by DCL and State Capital and Investment Corporation (SCIC).
